Perinatal Stroke: High-Dose Therapy Boosts Recovery

A new study presented at the American Stroke Association’s International Stroke Conference 2026 offers a significant, and surprisingly optimistic, shift in how we approach perinatal arterial ischemic stroke (PAIS) – the most common form of stroke in children. For years, the prognosis for infants experiencing stroke around the time of birth has been considered relatively grim. However, intensive, constraint-induced movement therapy (CIMT), delivered in the home, is demonstrating measurable and lasting improvements in motor skills, challenging those long-held assumptions and offering new hope for families.

PAIS occurs when blood supply to the developing brain is interrupted, often during or shortly after birth. This can lead to hemiparesis – weakness or paralysis on one side of the body – impacting a child’s ability to develop crucial motor skills. Traditionally, rehabilitation has focused on general physical and occupational therapy. This study, a Phase 3 randomized clinical trial involving 167 children aged 8 months to 36 months, rigorously tested the efficacy of CIMT, a technique designed to “rewire” the brain by forcing use of the affected limb.

The I-ACQUIRE treatment protocol involved either moderate (60 hours total) or high (120 hours total) doses of therapist-delivered therapy in the child’s home environment, coupled with the use of a lightweight cast to restrict movement of the stronger arm. The study’s design is particularly noteworthy; it addressed a critical gap in the literature. Prior to this research, clinicians often based treatment recommendations on studies primarily involving older children with cerebral palsy, a different neurological condition. This new data provides evidence specifically tailored to the unique developmental stage of infants and toddlers recovering from stroke.

The Forward Look

While the results are encouraging, several key areas require further investigation. The researchers noted that skill gains were smaller than initially anticipated, suggesting that children with PAIS may respond more variably to CIMT than previously observed in other populations. Identifying biomarkers or clinical characteristics that predict treatment response will be crucial. The Delayed Treatment Study, offering I-ACQUIRE therapy to children in the usual care group after the initial assessment, is a vital next step. This will provide further data on the long-term benefits and potential for catch-up growth in motor skills.

Perhaps the most significant takeaway is the shift in perspective regarding the potential for recovery after early stroke. As Dr. Ramey noted, parents consistently reported improvements exceeding their initial expectations. This underscores the importance of early intervention and a more optimistic outlook. We can anticipate a growing demand for specialized PAIS rehabilitation programs and increased investment in research focused on optimizing treatment strategies. Furthermore, the success of delivering therapy in the home setting suggests a scalable model for reaching families in diverse geographic locations. The field is poised to move beyond simply managing the effects of PAIS to actively maximizing functional outcomes and improving the quality of life for these young children and their families.

The limitations of the study – specifically the selection of participating sites based on resource availability and the reduced sample size due to diagnostic discrepancies – should be addressed in future research. Broader, more representative studies are needed to confirm these findings and refine the I-ACQUIRE protocol for optimal effectiveness across diverse populations.